Payment overview · 2025
General Payments
$18.89
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ellen H Kim, MD
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1912069329
Verified facts
What the public records show
CMS Open Payments records show Ellen H Kim, MD received $18.89 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.89 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.89 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 458 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 158 |
| Losartan Potassium | Losartan Potassium | 400 | 136 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 389 | 143 |
| Gabapentin | Gabapentin | 343 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 341 | 126 |
| Lisinopril | Lisinopril | 305 | 111 |
| Omeprazole | Omeprazole | 288 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 250 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 110 |
| Metformin Hcl | Metformin Hcl | 242 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 201 | 93 |
| Metformin Hcl Er | Metformin Hcl | 164 | 58 |
| Bupropion Xl | Bupropion Hcl | 160 | 45 |
| Trulicity | Dulaglutide | 154 | 32 |
| Methylprednisolone | Methylprednisolone | 152 | 115 |
| Trazodone Hcl | Trazodone Hcl | 139 | 49 |
| Prednisone | Prednisone | 133 | 91 |
| Famotidine | Famotidine | 118 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 40 |
| Azelastine Hcl | Azelastine Hcl | 104 | 40 |
| Mirtazapine | Mirtazapine | 103 | 45 |
| Carvedilol | Carvedilol | 100 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 39 |
| Simvastatin | Simvastatin | 97 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 92 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 48 |
| Eliquis | Apixaban | 89 | 29 |
| Alendronate Sodium | Alendronate Sodium | 87 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 86 | 40 |
| Sertraline Hcl | Sertraline Hcl | 84 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 52 |
| Furosemide | Furosemide | 79 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 58 |
| Montelukast Sodium | Montelukast Sodium | 70 | 32 |
| Glipizide | Glipizide | 68 | 30 |
| Ibuprofen | Ibuprofen | 65 | 30 |
| Buspirone Hcl | Buspirone Hcl | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 23 |
| Farxiga | Dapagliflozin Propanediol | 60 | 17 |
| Azithromycin | Azithromycin | 58 | 49 |
| Finasteride | Finasteride | 53 | 22 |
| Donepezil Hcl | Donepezil Hcl | 51 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 51 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 49 | 21 |
| Ozempic | Semaglutide | 49 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 17 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Valsartan | Valsartan | 46 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 25 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 43 | 21 |
| Jardiance | Empagliflozin | 41 | 15 |
| Naproxen | Naproxen | 40 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Myrbetriq | Mirabegron | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 37 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 15 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 31 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 14 |
| Nystatin | Nystatin | 31 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Atenolol | Atenolol | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 11 |
| Trospium Chloride | Trospium Chloride | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.89 · 1 records | ABBVIE INC. | VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error